| Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1425 | 2019 |
| PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes Z Sun, CW Arendt, W Ellmeier, EM Schaeffer, MJ Sunshine, L Gandhi, ... Nature 404 (6776), 402-407, 2000 | 1175 | 2000 |
| Complications after prostate biopsy: data from SEER-Medicare S Loeb, HB Carter, SI Berndt, W Ricker, EM Schaeffer The Journal of urology 186 (5), 1830-1834, 2011 | 882 | 2011 |
| Prostate cancer, version 1.2016 JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ... Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016 | 810 | 2016 |
| Complications after systematic, random, and image-guided prostate biopsy M Borghesi, H Ahmed, R Nam, E Schaeffer, R Schiavina, S Taneja, ... European urology 71 (3), 353-365, 2017 | 650 | 2017 |
| Infections of the urinary tract AJ Schaeffer Campbell-Walsh Urology, Tenth Edition, Vol 1, 257-326, 2012 | 608 | 2012 |
| Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 21 (10), 1067-1096, 2023 | 544 | 2023 |
| Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity EM Schaeffer, J Debnath, G Yap, D McVicar, XC Liao, DR Littman, A Sher, ... Science 284 (5414), 638-641, 1999 | 480 | 1999 |
| Association of black race with prostate cancer–specific and other-cause mortality RT Dess, HE Hartman, BA Mahal, PD Soni, WC Jackson, MR Cooperberg, ... JAMA oncology 5 (7), 975-983, 2019 | 466 | 2019 |
| NCCN guidelines insights: prostate cancer, version 1.2021: featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021 | 450 | 2021 |
| Prostate cancer, version 2.2014 JL Mohler, PW Kantoff, AJ Armstrong, RR Bahnson, M Cohen, ... Journal of the National Comprehensive Cancer Network 12 (5), 686-718, 2014 | 415 | 2014 |
| NCCN Guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ... Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022 | 336 | 2022 |
| Increasing incidence of metastatic prostate cancer in the United States (2004–2013) AB Weiner, RS Matulewicz, SE Eggener, EM Schaeffer Prostate cancer and prostatic diseases 19 (4), 395-397, 2016 | 332 | 2016 |
| Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy SG Zhao, SL Chang, N Erho, M Yu, J Lehrer, M Alshalalfa, C Speers, ... JAMA oncology 3 (12), 1663-1672, 2017 | 322 | 2017 |
| Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations JJ Tosoian, MA Gorin, AE Ross, KJ Pienta, PT Tran, EM Schaeffer Nature Reviews Urology 14 (1), 15-25, 2017 | 314 | 2017 |
| A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes SA Boorjian, JA Eastham, M Graefen, B Guillonneau, RJ Karnes, JW Moul, ... European urology 61 (4), 664-675, 2012 | 312 | 2012 |
| Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men AE Ross, MH Johnson, K Yousefi, E Davicioni, GJ Netto, L Marchionni, ... European urology 69 (1), 157-165, 2016 | 284 | 2016 |
| Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease DE Spratt, K Yousefi, S Deheshi, AE Ross, RB Den, EM Schaeffer, ... Journal of Clinical Oncology 35 (18), 1991-1998, 2017 | 268 | 2017 |
| African American men with very low–risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? D Sundi, AE Ross, EB Humphreys, M Han, AW Partin, HB Carter, ... Journal of clinical oncology 31 (24), 2991-2997, 2013 | 267 | 2013 |
| Pre-processing Agilent microarray data M Zahurak, G Parmigiani, W Yu, RB Scharpf, D Berman, E Schaeffer, ... BMC bioinformatics 8 (1), 142, 2007 | 264 | 2007 |
